Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Sichuan Baili Pharmaceutical Co., Ltd.
ImmunoGenesis
Genentech, Inc.
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
BeOne Medicines
Servier
Children's National Research Institute
M.D. Anderson Cancer Center
Chugai Pharmaceutical
Georgetown University
Eisai Inc.
Zhejiang University
Axcynsis Therapeutics Pte Ltd
Suzhou Biomissile Pharmaceuticals Co., Ltd.
Gilead Sciences
Boundless Bio, Inc.
Byondis B.V.
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ono Pharmaceutical Co. Ltd
RemeGen Co., Ltd.
Guangzhou Virotech Pharmaceutical Co., Ltd.
PAQ Therapeutics, Inc.
Sichuan University
SPARK Biopharma
Binhui Biopharmaceutical Co., Ltd.
Biohaven Pharmaceuticals, Inc.
Masonic Cancer Center, University of Minnesota
Eli Lilly and Company
Fox Chase Cancer Center
Abbisko Therapeutics Co, Ltd
Bliss Biopharmaceutical (Hangzhou) Co., Ltd
Sichuan Baili Pharmaceutical Co., Ltd.
Oxford BioTherapeutics Ltd
Sanofi
Impact Therapeutics, Inc.
Impact Therapeutics, Inc.
Impact Therapeutics, Inc.
SmartNuclide Biopharma
MapKure, LLC
L & L Bio Co., Ltd., Ningbo, China
Pyxis Oncology, Inc
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Bliss Biopharmaceutical (Hangzhou) Co., Ltd
University of California, San Francisco
Genmab
Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.
Byondis B.V.
Zhejiang Doer Biologics Co., Ltd.